ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,444Medicare Part D Prescriptions Filled, Including Refills

Rank: 111 out of 1269

$540K Total Retail Price of All Prescriptions

Rank: 127 out of 1269

422 Patients Receiving at Least One Drug in Part D
77%Patients 65 Years and Older
41% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

9% of this provider’s 422 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

17% of this provider’s 422 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

2% of this provider’s 6,186 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$64 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
HYDROCODONE-ACETAMINOPHEN 254 140 S3 1 20
WARFARIN SODIUM 251 177 2 12
AMLODIPINE BESYLATE 229 204 3 2
LEVOTHYROXINE SODIUM 223 162 4 4
PRAVASTATIN SODIUM 223 191 4 11
SIMVASTATIN 222 159 6 3
OMEPRAZOLE 219 143 7 8
METOPROLOL TARTRATE 215 198 8 6
LISINOPRIL 208 170 9 1
METFORMIN HCL 150 131 10 9
ZOLPIDEM TARTRATE 145 86 11 19
HYDROCHLOROTHIAZIDE 143 135 12 10
FUROSEMIDE 128 109 13 5
ATORVASTATIN CALCIUM 115 90 14 7
ATENOLOL 112 105 15 14
POTASSIUM CHLORIDE 109 109 16 26
DOXAZOSIN MESYLATE 105 89 17 117
ISOSORBIDE MONONITRATE ER 105 96 17 63
MELOXICAM 102 86 19 68
PANTOPRAZOLE SODIUM 100 78 20 18
RANITIDINE HCL 94 63 21 27
OXYCODONE-ACETAMINOPHEN 91 33 S2 22 44
LOSARTAN POTASSIUM 90 71 23 15
LISINOPRIL-HYDROCHLOROTHIAZIDE 89 71 24 33
FLUOXETINE HCL 89 71 24 83
PREDNISONE 85 69 26 45
METOPROLOL SUCCINATE 83 67 27 13
PROMETHAZINE HCL 79 25 R 28 149
MORPHINE SULFATE ER 77 34 S2 29 118
LOVASTATIN 77 70 29 30
GABAPENTIN 73 59 31 17
NEXIUM 71 42 32 41
CLOPIDOGREL 70 60 33 32
ENALAPRIL MALEATE 66 63 34 79
LOSARTAN-HYDROCHLOROTHIAZIDE 62 46 35 59
PLAVIX 60 54 36 47
CITALOPRAM HBR 59 36 37 21
FLUTICASONE PROPIONATE 57 47 38 40
GLIPIZIDE 57 47 38 37
GLIPIZIDE ER 56 41 40 102
CYCLOBENZAPRINE HCL 55 36 R 41 93
DIGOXIN 53 45 42 62
CRESTOR 53 37 42 25
AZITHROMYCIN 52 38 44 42
SERTRALINE HCL 50 28 45 23
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 4, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.